aka Trans Pacific Partnership

*The 2005 Trans-Pacific Strategic Economic Partnership Agreement (TPSEP or P4) is a Free Trade agreement among Brunei, Chile, New Zealand, and Singapore. It aims to further liberalise the economies of the Asia-Pacific region.[7]

Since 2010, negotiations have been taking place[8] for the Trans-Pacific Partnership (TPP), a proposal for a significantly expanded version of TPSEP. The TPP is a proposed free trade agreement under negotiation by (as of August 2013) Australia, Brunei, Chile, Canada, Japan,[9] Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam.[10]

The TPP is ostensibly intended to be a "high-standard" agreement specifically aimed at emerging trade issues in the 21st century.[11] These ongoing negotiations have drawn criticism and protest from the public, advocacy groups, and elected officials, in part due to the secrecy of the negotiations, the expansive scope of the agreement, and a number of controversial clauses in drafts leaked to the public.

On November 13, 2013, a complete draft of the treaty's Intellectual Property Rights chapter was published by WikiLeaks.[12]*

EFF: Even as the public has been completely shut out, the U.S. Trade Representative (USTR) has lobbied for wider latitude to negotiate and for “Fast Track authority” to bypass Congressional review... The leaked draft includes controversial language calling for laws prohibiting the circumvention of “technological protection measures,” also known as DRM.

  • EFF stream -

Some provisions of the text resurrect pieces of SOPA and PIPA and ACTA that many found to be objectionable... U.S. copyright holders would like ISP-s to be held liable for hosting infringing content. The United States also proposes extending copyright to life plus 95 years for corporate-owned copyrights... several provisions would support the pharmaceutical firms’ (PharmCo) practice of “ever-greening” in which a firm will hold a Patent on drug ‘x’ in tablet form, then later obtain a patent on drug ‘x’ in a gel cap, and later still obtain another patent on the same drug in capsule form. This extends patent life on a known substance, despite no new medical efficacy; thus it delays generic competition... I expect that the release of this text will increase Congressional opposition to extending Fast Track negotiating authority to President Obama. Congress has already expressed displeasure at being shut out of this process.

Edited: |

blog comments powered by Disqus